United States · Markets & Finance · Morningstar

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

Published by Morningstar · United States 18 h ago

NORTH CHICAGO, Ill., Oct. 11, 2026 /PRNewswire/ -- AbbVie today announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD)…

Read the full article on Morningstar Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)

Also worth reading

TechCrunch

The investor’s guide to TechCrunch Disrupt 2026: Everything you need to know

Seeking Alpha

Starknet coin surges as developer weighs Ethereum split over quantum security

Fortune

For the first time ever, 10-year bond yields track diesel prices more closely than crude, and Trump’s fuel deal with Putin may be too little too late

Decrypt

Tokenized Stocks Show Real Demand But Remain Volatile and Illiquid, IMF Finds

CNBC

From BJ’s to Lululemon, retailers are trimming assortments to boost business

Cointelegraph